Tharimmune, Inc. — Director's Dealing 2022

Mar 23, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-03-21

Reporting Person: Bui Lynne A. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-21	Options (right to buy)	$1.33	A	50000	Acquired	2032-03-21	Common stock (50000)	Direct

Footnotes

F1: On March 21, 2022, the Reporting Person was granted options ("Options") to purchase up to 50,000 shares of the Registrant's common stock pursuant to the Registrant's 2019 Stock Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant.